Paxil Lawsuit Ends with Jury Verdict of $2.5 Million

The first Paxil lawsuit has finally gone to trial and the jury has awarded a suburban Philadelphia family $2.5 million. GlaxoSmithKline has been ordered to pay the monetary damages for birth defects suffered by a young child whose mother took the anti-depressant drug. The jury awarded the family double the amount they sought because they found that GlaxoSmithKline failed to warn doctors of the potentially serious birth defects associated with Paxil.
Paxil belongs to a family of drugs known as selective serotonin reuptake inhibitors (SSRI) and GlaxoSmithKline was warned about the drug’s link to serious birth defects in 2005. Yet, the company chose to minimize the association and decided to downplay the risks when discussing the drug with doctors.
As in many of our lawsuits, the company’s own internal documents provided the damning evidence of misbehavior and mischaracterization of the drug’s real dangers.
While GlaxoSmithKline says it will appeal the jury verdict, it faces 600 similar Paxil birth defect lawsuits.